Champions Oncology, Inc. (NASDAQ:CSBR)
Industry: Healthcare

Listed 4 Consecutive Market Days. On List as of 01/09/2007 Through 09/16/2016

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. The company markets its products through Internet, word of mouth, and sales force to patients and physicians. Champions Oncology, Inc. has collaboration partnerships with NSABP Foundation, Inc. and Puma Biotechnology, Inc. to develop patient derived xenograft models in two multi-center co-clinical patient derived xenograft trials. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Current Quote*
Last: $7.650
Change: -0.120
Book: $39.637
Volume: 16,570

As Of: 07/19 13:10 ET
*Quotes delayed by 20min.

Graphs for CSBR


3 Month Graph


6 Month Graph


1 Year Graph